“I think the reason the LH protocol is taking so
Post# of 148158
IMO, regardless of the statistical significance of the phase 2 trial, a larger phase 3 will be needed. The trial size is small and unlikely to satisfy FDA requirements for an approval. Our M2M trial would’ve required a larger phase 3 if the primary endpoint has been met. I’m sure some will mention EUA, but I’m not sure if longhaulers is a disease that meets that criteria.